KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Other Non-Current Liabilities (2019 - 2025)

Royalty Pharma's Other Non-Current Liabilities history spans 5 years, with the latest figure at $577.9 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities changed N/A year-over-year to $577.9 million; the TTM value through Dec 2025 reached $577.9 million, changed N/A, while the annual FY2025 figure was $577.9 million, N/A changed from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $577.9 million at Royalty Pharma, up from $126.9 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $577.9 million in Q4 2025 and bottomed at $900000.0 in Q4 2023.
  • The 4-year median for Other Non-Current Liabilities is $11.8 million (2023), against an average of $70.8 million.
  • The largest annual shift saw Other Non-Current Liabilities tumbled 80.55% in 2023 before it skyrocketed 2174.98% in 2025.
  • A 4-year view of Other Non-Current Liabilities shows it stood at $2.5 million in 2022, then tumbled by 64.0% to $900000.0 in 2023, then soared by 520.0% to $5.6 million in 2024, then skyrocketed by 10256.09% to $577.9 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Other Non-Current Liabilities are $577.9 million (Q4 2025), $126.9 million (Q3 2025), and $143.3 million (Q2 2025).